How Janssen Immunology is Using Immune Pathway Science to Treat Rare Diseases
Neely Mozaffarian, M.D., Ph.D., is a Vice President and Autoantibody Pathway Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this segment, she discusses how Janssen is advancing autoantibody science through a novel immune pathway approach and innovating treatments for rare immune-mediated diseases, like hemolytic disease of the fetus and newborn (HDFN) and warm autoimmune hemolytic anemia (wAIHA.) One investigational therapy, nipocalimab, is currently in clinical trials for several immune-mediated rare diseases which share the same autoantibody pathway and is not FDA approved.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Therapy?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Neely Mozaffarian, M.D., Ph.D., is Vice President Autoantibody Pathway Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Neely is responsible for the design and implementation of the scientific strategy for the Autoantibody Pathway portfolio, partnering with teams across the Janssen therapeutic area to identify external opportunities and platforms required for next-generation approaches to the autoantibody pathway targets.
Prior to her role at Janssen, Neely led a team in global clinical drug development for small and large molecules and was responsible for strategy and deliverables for autoimmunity and rheumatology programs as Senior Vice President at Ichnos Sciences, a subsidiary of Glenmark Sciences.
Prior to joining Ichnos, Neely served as Group Leader, Global Autoimmunity and Rheumatology Clinical Research and as Executive Director, Clinical Research, Inflammation and Respiratory Therapeutics at Gilead Sciences. Before joining Gilead, she held positions focusing on rheumatology and immunology at Lilly, AbbVie and Bristol Myers Squibb.
Neely earned her M.D. and Ph.D. degrees from Albert Einstein College of Medicine in New York. She trained in internal medicine and rheumatology at the University of Washington, Seattle and has authored numerous abstracts and scientific articles.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
